HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tomasz Skorski Selected Research

1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)

1/2022Synthetic Lethality Targeting Polθ.
10/2020TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.
12/2018Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.
1/2017IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
11/2016PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
2/2012BCR-ABL1 kinase facilitates localization of acetylated histones 3 and 4 on DNA double-strand breaks.
2/2011BCR/ABL stimulates WRN to promote survival and genomic instability.
9/2008BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
6/2002Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tomasz Skorski Research Topics

Disease

37Leukemia
01/2022 - 01/2002
28BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2021 - 08/2002
23Neoplasms (Cancer)
10/2022 - 05/2002
12Genomic Instability
10/2018 - 05/2002
5Chromosome Aberrations (Chromosome Abnormalities)
05/2013 - 09/2008
4Genetic Translocation (Chromosomal Translocation)
04/2008 - 06/2002
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2021 - 01/2018
3Philadelphia Chromosome
10/2005 - 08/2002
3Lymphoma (Lymphomas)
06/2002 - 01/2002
2Breast Neoplasms (Breast Cancer)
06/2020 - 10/2018
2Prostatic Neoplasms (Prostate Cancer)
01/2019 - 05/2005
2Disease Progression
01/2018 - 07/2011
2Glioma (Gliomas)
07/2017 - 11/2016
2Carcinoma (Carcinomatosis)
01/2016 - 08/2013
2Myeloproliferative Disorders (Myeloproliferative Disorder)
06/2012 - 09/2008
2Blast Crisis (Blast Phase)
07/2011 - 09/2008
2Lymphoid Leukemia
10/2005 - 08/2002
2Myeloid Leukemia (Leukemia, Myelocytic)
11/2004 - 11/2002
2Non-Hodgkin Lymphoma (Lymphosarcoma)
03/2003 - 06/2002
1Hypoxia (Hypoxemia)
10/2020
1Carcinogenesis
01/2019
1Glioblastoma (Glioblastoma Multiforme)
12/2018
1Hypersensitivity (Allergy)
01/2017
1Burkitt Lymphoma (Burkitt's Lymphoma)
01/2017
1Melanoma (Melanoma, Malignant)
11/2016
1Aneuploidy (Aneuploid)
01/2014
1Chromosomal Instability (Chromosome Stability)
07/2011
1Werner Syndrome (Werner's Syndrome)
02/2011

Drug/Important Bio-Agent (IBA)

19Phosphotransferases (Kinase)IBA
10/2020 - 05/2002
17DNA (Deoxyribonucleic Acid)IBA
01/2022 - 05/2002
17Imatinib Mesylate (Gleevec)FDA Link
01/2021 - 08/2002
13Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
10/2019 - 01/2002
91,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
01/2022 - 06/2002
8Reactive Oxygen Species (Oxygen Radicals)IBA
01/2018 - 05/2007
7Tyrosine Kinase InhibitorsIBA
01/2021 - 02/2011
7Proteins (Proteins, Gene)FDA Link
01/2021 - 04/2004
6Poly(ADP-ribose) Polymerase InhibitorsIBA
10/2021 - 12/2017
6Pharmaceutical PreparationsIBA
10/2019 - 12/2002
5Tyrosine (L-Tyrosine)FDA Link
08/2011 - 05/2002
4olaparibIBA
06/2020 - 11/2016
4bcr-abl Fusion ProteinsIBA
05/2007 - 12/2004
4Anaplastic Lymphoma KinaseIBA
12/2004 - 01/2002
3Serine (L-Serine)FDA Link
01/2021 - 05/2006
3talazoparibIBA
12/2018 - 01/2017
3Peptides (Polypeptides)IBA
08/2013 - 07/2011
3Cisplatin (Platino)FDA LinkGeneric
05/2006 - 05/2005
2Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
10/2019 - 07/2007
2NAD (NADH)IBA
01/2019 - 01/2019
2Alkylating AgentsIBA
12/2018 - 11/2016
2DNA Ligases (Ligases, DNA)IBA
12/2018 - 11/2016
2BRCA1 ProteinIBA
10/2018 - 01/2014
2EnzymesIBA
01/2018 - 11/2016
2AntioxidantsIBA
01/2018 - 07/2006
2Therapeutic UsesIBA
08/2017 - 01/2017
2Mitomycin (Mitomycin-C)FDA LinkGeneric
02/2012 - 05/2006
2Histones (Histone)IBA
02/2012 - 05/2006
2Oncogene Proteins (Oncogene Protein)IBA
07/2010 - 11/2004
2Complementary DNA (cDNA)IBA
04/2006 - 06/2003
1Type II Tumor Necrosis Factor ReceptorsIBA
01/2022
1Interleukin-21 ReceptorsIBA
01/2022
1DioxygenasesIBA
10/2021
1NucleotidesIBA
01/2021
1Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric
01/2021
1Staphylococcal Protein A (Protein A)IBA
01/2021
1Transforming Growth Factor beta (TGF-beta)IBA
10/2020
1Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA
10/2020
1poly ADP-ribose glycohydrolaseIBA
01/2019
1Temozolomide (Temodar)FDA LinkGeneric
12/2018
1RNA-Binding Proteins (RNA-Binding Protein)IBA
10/2018
1fms-Like Tyrosine Kinase 3IBA
01/2018
1Protein Kinase CIBA
01/2018
1Protein Kinase C-epsilonIBA
01/2018
1ruxolitinibIBA
12/2017
1Messenger RNA (mRNA)IBA
07/2017
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
06/2017
1DNA-Activated Protein KinaseIBA
06/2017
1Cytarabine (Cytosar-U)FDA LinkGeneric
01/2017
1ElementsIBA
01/2017
1Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA
01/2017
1Conditioned Culture MediaIBA
11/2016
1Ligases (Synthetase)IBA
11/2016
1Dacarbazine (DIC)FDA LinkGeneric
11/2016
1RibonucleotidesIBA
01/2016
1Phosphates (Orthophosphate)IBA
01/2016
1AICA ribonucleotide (ZMP)IBA
01/2016
1ponatinibIBA
01/2016
1Adenosine (Adenocard)FDA LinkGeneric
01/2016
1SolutionsIBA
09/2014
1Phenylalanine (L-Phenylalanine)FDA Link
08/2013
1CatalaseIBA
05/2012
1Histone Acetyltransferases (Histone Acetyltransferase)IBA
02/2012
1Histone Deacetylases (Histone Deacetylase)IBA
02/2012
1Cytotoxins (Cytolysins)IBA
02/2012
1ChromatinIBA
02/2012
1Dasatinib (BMS 354825)FDA Link
02/2011

Therapy/Procedure

12Therapeutics
10/2022 - 04/2008
3Drug Therapy (Chemotherapy)
01/2022 - 01/2017
3Precision Medicine
06/2020 - 11/2015
2Aftercare (After-Treatment)
11/2016 - 05/2006
1Radiotherapy
12/2018